Literature DB >> 21710622

Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions.

María I Gaitán1, Colin D Shea, Iordanis E Evangelou, Roger D Stone, Kaylan M Fenton, Bibiana Bielekova, Luca Massacesi, Daniel S Reich.   

Abstract

OBJECTIVE: Multiple sclerosis (MS) lesions develop around small, inflamed veins. New lesions enhance with gadolinium on magnetic resonance imaging (MRI), reflecting disruption of the blood-brain barrier (BBB). Single time point results from pathology and standard MRI cannot capture the spatiotemporal expansion of lesions. We investigated the development and expansion of new MS lesions, focusing on the dynamics of BBB permeability.
METHODS: We performed dynamic contrast-enhanced (DCE) MRI in relapsing-remitting MS. We obtained data over 65 minutes, during and after gadolinium injection. We labeled spatiotemporal enhancement dynamics as centrifugal when initially central enhancement expanded outward and centripetal when initially peripheral enhancement gradually filled the center.
RESULTS: We detected 34 enhancing lesions in 200 DCE-MRI scans. In 65%, enhancement first appeared as a closed ring; in 18%, as a nodule; and in 18%, as an open ring. Lesions with initially nodular enhancement were smaller than those initially enhancing as rings (p < 0.0001). All initially nodular lesions enhanced centrifugally, whereas initially ringlike lesions enhanced centripetally, becoming nodular if small (82%) or nearly nodular if larger (18%). Open-ring lesions were periventricular or juxtacortical and enhanced centripetally. Centrifugally enhancing lesions evolved into centripetally enhancing lesions over several days.
INTERPRETATION: The rapid change of enhancement dynamics from centrifugal to centripetal reflects the outward growth of MS lesions around their central vein and suggests that factors mediating lesion growth and tissue repair derive from different locations at different times. We propose a model of new lesion growth that unites our imaging observations with existing pathology data.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Year:  2011        PMID: 21710622      PMCID: PMC3143223          DOI: 10.1002/ana.22472

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  36 in total

1.  Enhancing patterns in multiple sclerosis: evolution and persistence.

Authors:  J He; R I Grossman; Y Ge; L J Mannon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

2.  MR venography of multiple sclerosis.

Authors:  I L Tan; R A van Schijndel; P J Pouwels; M A van Walderveen; J R Reichenbach; R A Manoliu; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

3.  Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study.

Authors:  Jens Wuerfel; Judith Bellmann-Strobl; Peter Brunecker; Orhan Aktas; Henry McFarland; Arno Villringer; Frauke Zipp
Journal:  Brain       Date:  2003-10-21       Impact factor: 13.501

4.  Ring-enchancement in multiple sclerosis: marker of disease severity.

Authors:  K Morgen; N O Jeffries; R Stone; R Martin; N D Richert; J A Frank; H F McFarland
Journal:  Mult Scler       Date:  2001-06       Impact factor: 6.312

5.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse.

Authors:  D J Mahad; J Lawry; S J L Howell; M N Woodroofe
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

Review 7.  Enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  M Filippi
Journal:  Mult Scler       Date:  2000-10       Impact factor: 6.312

8.  Open-ring imaging sign: highly specific for atypical brain demyelination.

Authors:  J C Masdeu; C Quinto; C Olivera; M Tenner; D Leslie; P Visintainer
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

Review 9.  The blood-brain barrier, chemokines and multiple sclerosis.

Authors:  David W Holman; Robyn S Klein; Richard M Ransohoff
Journal:  Biochim Biophys Acta       Date:  2010-08-06

10.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study.

Authors:  D J Werring; D Brassat; A G Droogan; C A Clark; M R Symms; G J Barker; D G MacManus; A J Thompson; D H Miller
Journal:  Brain       Date:  2000-08       Impact factor: 13.501

View more
  72 in total

1.  The mechanisms of cerebral vascular dysfunction and neuroinflammation by MMP-mediated degradation of VEGFR-2 in alcohol ingestion.

Authors:  P M Abdul Muneer; Saleena Alikunju; Adam M Szlachetka; James Haorah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

2.  Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Authors:  Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham
Journal:  Neuroimage       Date:  2017-01-11       Impact factor: 6.556

3.  Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging.

Authors:  Daniel S Reich; Richard White; Irene Cm Cortese; Luisa Vuolo; Colin D Shea; Tassie L Collins; John Petkau
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

4.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

5.  Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?

Authors:  Constantina Andrada Treabă; Rodica Bălaşa; Daniela Maria Podeanu; Iunius Paul Simu; Mircea Marian Buruian
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

Review 6.  Current and new directions in MRI in multiple sclerosis.

Authors:  Eric C Klawiter
Journal:  Continuum (Minneap Minn)       Date:  2013-08

7.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

8.  Netrin 1 regulates blood-brain barrier function and neuroinflammation.

Authors:  Cornelia Podjaski; Jorge I Alvarez; Lyne Bourbonniere; Sandra Larouche; Simone Terouz; Jenea M Bin; Marc-André Lécuyer; Olivia Saint-Laurent; Catherine Larochelle; Peter J Darlington; Nathalie Arbour; Jack P Antel; Timothy E Kennedy; Alexandre Prat
Journal:  Brain       Date:  2015-04-22       Impact factor: 13.501

Review 9.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

10.  Initial investigation of the blood-brain barrier in MS lesions at 7 tesla.

Authors:  María I Gaitán; Pascal Sati; Souheil J Inati; Daniel S Reich
Journal:  Mult Scler       Date:  2012-12-17       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.